跳至主要内容
临床试验/NL-OMON41799
NL-OMON41799已完成2 期

Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients - [18F]DPA-714 PET in MS

Vrije Universiteit Medisch Centrum0 个研究点目标入组 23 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
23

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - For the MS patient group: diagnosis primary or secondary progressive MS with EDSS scores 4.0 to 7.5
  • - 18 to 60 years
  • - Written informed consent
  • - No immunomodulating or immunosuppressive treatment in previous three months

排除标准

  • - Inability to undergo MRI, e.g. metal objects in or around the body, claustrophobia or inability to lie still in the scanner. For the MS patients: contra-indication for gadolinium administration, e.g. previous allergic reaction to gadolinium.
  • - Homozygote Ala(147)Thr genotype (low-affinity binders)
  • - Significant immune disease other than MS
  • - (History of) other relevant neurological disease
  • - History of malignancy
  • - Known significant cardiac disease
  • - Inadequate renal function: creatinine clearance <60 ml/min
  • - Loss or donation of blood over 500 mL within four months prior to screening.
  • - In male subjects Hb <8.0 g/dL, in female subjects Hb <7.0 g/dL
  • - Pregnant or breast feeding
  • - (History of) alcohol and/or drug abuse
  • - Exposure to previous radiation leading to annual cumulative dose of more than 10 mSV if participating in this protocol
  • - Use of benzodiazepines within 1 week of the PET scan

研究者

相似试验

Grey matter microglial imaging with [18F]DPA-714 in... | 临床试验